Neoantigens are tumor-specific antigens that are developed from mutated proteins only found in cancer cells. Neoantigen cancer vaccines are novel vaccines that utilize neoantigens to boost the immune system against tumor cells. The Neoantigen cancer vaccine Market is expected to grow at a steady rate of around 25% during the forecast period (2022-2028).
Unlock Insights: Receive a Sample Research Report on the Neoantigen Cancer Vaccine Market - https://univdatos.com/get-a-free-sample-form-php/?product_id=35835
Owing to this high specificity towards cancer cells, these vaccines have gained considerable momentum in the global market. Pharmaceutical companies is tremendously investing in research activities for the development of neoantigen cancer vaccines. For instance, in October 2020, Vaccibody signed an agreement with Genentech for the development and commercialization of DNA-based individualized neoantigen cancer vaccines.
The market is growing at a tremendous rate owing to the increase in the incidences of cancers, the rise in the adoption of personalized medicine to tailor patient treatment on an individual level, and huge funding for conducting research and development activities. For instance, in January 2023, Greenlight Bioscience entered into collaboration with EpiVax Therapeutics to jointly develop and commercialize personalized mRNA-based vaccine candidates for cancers.
According to UnivDatos Market Insights (UMI)’ research report “Global Neoantigen cancer vaccine Market”, the market is expected to witness robust growth during the forecast period (2022-2028) owing to surge in the prevalence of cancer. According to GLOBOCAN, in 2020, there were about 19.3 million new cancer cases and approximately 10 million deaths. Thus, the surge in the incidences of cancer is expected to foster the adoption of neoantigen cancer vaccines. Moreover, the rising initiatives of the government and various non-profit organizations in spreading awareness regarding the prevention of cancer are expected to fuel the growth of the market. For instance, the World Health Organization’s Global Action Plan for Prevention and Control of Non-Communicable Diseases aims at decreasing premature death due to cancer, cardiovascular diseases, chronic respiratory diseases, and diabetes by around 25% by the year 2025.
Based on product, the market is bifurcated into personalized neoantigen vaccine and off-the shelf neoantigen vaccine. Among these, off-the shelf neoantigen vaccine held a dominant share in the market in 2021 as their manufacturing requires less source and time. Moreover, a large number of ongoing clinical trials and their encouraging results are other factors driving the segmental growth. For instance, in May 2022, Nouscom presented the promising result of phase-I trial evaluating NOUS-209, off-the shelf, and personalized viral vectored immunotherapies in combination with PD-1 checkpoint inhibitors for the treatment of solid tumors.
Based on neoantigen type, the market is segmented into a nucleic acid, dendritic cell, tumor cell, and synthetic long peptide. The nucleic acid category is expected to hold a significant share of the market during the forecast period due to the rise in the number of product pipelines and their encouraging response in the clinical trials. For instance, in October 2021, BioNTech dosed first patient with individualized mRNA vaccine, autogene cevumeran in the adjuvant treatment of circulating tumor DNA (ctDNA) positive, surgically resected Stage II (high-risk)/Stage III colorectal cancer.
Based on application, the market is segmented into melanoma, breast cancer, gastrointestinal, lung cancer, and others. The melanoma category held a significant share of the market in 2021 due to a surge in the incidences of melanoma. According to the American Cancer Society, approximately 97,610 new melanomas will be diagnosed in 2023. Moreover, the unmet need for targeted therapy and the rising number of ongoing clinical trials is also driving segmental growth. For instance, according to a study published in Nature Medicine, a personalized long-peptide vaccine that can target up to 20 personal neoantigens per patient has been successful in preventing melanoma in patients at high risk for recurrence.
Based on therapy type, the market is bifurcated into mono therapeutic regimens and combinational regimens. The combinational regimens is anticipated to grow with significant CAGR during the forecast period owing to their advantages in terms of efficacy and safety in comparison to mono therapeutic regimens. Moreover, the large number of ongoing clinical trials also suggests a promising future for this category. For instance, in October 2021, Innovent Biologics entered into a strategic collaboration with NeoCura to evaluate the combination of sintilimab from Innovent and individualized neoantigen vaccine NEO_PLIN2101 from NeoCura in multiple solid tumors.
APAC to witness extensive growth
For a better understanding of the market adoption of the neoantigen cancer vaccine industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. APAC is anticipated to grow at a substantial CAGR during the forecast period mainly due to the surge in the prevalence of various cancers. According to the report titled "Cancer statistics in China and U.S., 2022: profiles, trends, and determinants" published in February 2022, compared to the 4,568,754 new cancer cases in China in 2020, the predicted number of new cancer cases for 2022 is 4,820,000. This increase in the new cases will directly increase the demand for cancer therapy, thus helping in the growth of the market during the study period. Moreover, domestic companies are also tremendously investing to gain a competitive edge in the market. For instance, in July 2020, Aichi Cancer Center collaborated with NEC Corporation to initiate a research study aiming to identify suitable neoantigens for vaccine use by using the neoantigen prediction system.
Explore the Comprehensive Research Overview, Including a Table of Contents, on the Neoantigen Cancer Vaccine Market - https://univdatos.com/report/neoantigen-cancer-vaccine-market
According to UnivDatos Market Insights (UMI)’, the key players with a considerable market share in the neoantigen cancer vaccine market are F. Hoffmann-La Roche Ltd; AstraZeneca; Merck & Co., Inc.; Gritstone bio; ose-immuno; BioNTech SE; Agenus Inc.; Gilead Sciences, Inc.; BrightPath Biotherapeutics Co., Ltd; and Innovent.
“Global Neoantigen cancer vaccine Market” provides comprehensive qualitative and quantitative insights on the industry potential, key factors impacting sales and purchase decisions, hotspots, and opportunities available for the market players. Moreover, the report also encompasses the key strategic imperatives for success for competitors along with strategic factorial indexing measuring competitors’ capabilities on different parameters. This will help companies in the formulation of go-to-market strategies and identifying the blue ocean for its offerings.
Contact Us:
UnivDatos Market Insights
Email - [email protected]
Website - https://univdatos.com/
COVID-19 Impact Analysis on Peptide Cancer Vaccine Market report published by Value Market Research provides a detailed market analysis comprising market size, share, value, growth and trends for the period 2020-2027.
Moreover, this market report also covers regional and country markets in detail.The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide.
This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.Get more information on "Global Peptide Cancer Vaccine Market Research Report" by requesting FREE Sample Copy at https://www.valuemarketresearch.com/contact/peptide-cancer-vaccine-market/download-sampleMarket DynamicsThe peptide cancer vaccine market is anticipated to achieve substantial growth during the forecast period.
It is expected that most of these vaccines targeting different types of cancer will gain necessary approvals within the next 4 to 5 years.
However, the peptide cancer vaccine has some significant shortcomings, including high cost, a sophisticated therapeutic routine, and a longer half-life.
Other factors restricting market growth are inadequate supply, particularly in remote areasThe research report covers Porter’s Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis.
